Daily equity-report by epic research 25 feb 2013
-
date post
20-Oct-2014 -
Category
Documents
-
view
170 -
download
1
Embed Size (px)
description
Transcript of Daily equity-report by epic research 25 feb 2013

-=6 HEADLINES
Indian Market
Indian equity markets were down 0.03%
Nifty down by 1.95 pts and settle at 5850.30
Sensex down by 8.35 pts at 19317.01
Bank Nifty up by 19.60 pts at 12100.50
Global Market
European markets were up with FTSE up by 48.51 closed at 6340 ,CAC up by 46.81 closed at 3671 and DAX up by 41.73 closed at 7625.
Dow future was up 34.00 closed at
13906.00
WWW.EPICRESEARCH.CO 09752199966
DAILY EQUITY NEWSLETTER 25TH FEBRUARY 2013
HEADLINES
• RBI officials fear Budget choices give
less room for rate cuts
• Jet Airways falls 5% on concerns over
Etihad deal
• SME: Channel Nine Entertainment IPO
opens for subscription
• Ex-Infosys executive aims to shake up IT
industry billing model

FII’s and DII’s
CATEGORY DATE BUY SELL NET
FII 22-Feb-13 2864.02 2583.72 280.3
DII 22-Feb-13 937.21 1289.19 -351.98
NIFTY DAILY PIVOTS
PIVOT R4 R3 R2 R1 PP S1 S2 S3 S4
NIFTY 6103 6026 5949 5900 5872 5823 5795 5718 5641
WWW.EPICRESEARCH.CO 09752199966
MARKET ANALYSIS:
Key benchmark indices reversed intraday gains and slipped into the red in late trade as index
heavyweight ITC dropped and as another index heavyweight Reliance Industries (RIL) trimmed
intraday gains. The market breadth, indicating the overall health of the market, turned negative from
positive in late trade, having alternately moved between positive and negative zone throughout the
trading session.
BSE Sensex was down 16.20 points or 0.08% to 19,309.16.
CNX Nifty was down 3.90 points or 0.07% to 5,848.35.
Among the 30-share Sensex pack, 16 stocks gained while the rest of them declined.
Sun Pharmaceutical Industries rose 2.04% to Rs 811.90 after striking a record high of Rs 814.20 in
intraday trade today, 22 February 2012. State run National Thermal Power Corporation (NTPC) rose
0.16%. NTPC has tied up a term loan facility of $250 million with State Bank of India, New York
Branch and Mizuho Corporate Bank, Singapore Branch as Arrangers and Lenders. The loan agreement
signed in New York by Mr. A.K. Singhal, Director (Finance), empowers NTPC for utilization of the
proceeds of the loan towards capital expenditure for procurement of goods and services for the ongoing
and new projects and renovation and modernization of power generation stations of the company. Bhel
took over BHPV as its 100% subsidiary in 2008. However, the company's performance was not upto
the mark, as it remained a separate company and it could not derive full benefits of synergy with Bhel.
STOCKS TO WATCH
ANDHRA BANK
AUROBINDO PHARMA
AMBUJA
BHARTI AIRTEL
SCRIPS IN BAN PERIOD
HDIL
PUNJLYOD
SUZLON
RENUKA
WELCORP

WWW.EPICRESEARCH.CO 09752199966
.
EXPERT OPINION
NIFTY
Nifty looks Consolidate
Strategy: Sell on rise
Support: 5800
Resistance: 5900
BANK NIFTY
Bank Nifty looks Consolidate
Strategy: Sell on rise
Support: 12040
Resistance: 12170
460
.0
GAINERS AND LOOSERS
PREVIOUS PERFORMANCE
TYPE SCRIP B/S RESULT
CASH ADANI POWER
S NOT
EXECUTED
CASH SESA GOA S SL TRIGERRED
FUTURE PUNJ LLYOD S SL TRIGERRED
FUTURE RELIANCE POWER
S SL TRIGERRED
UPCOMING RESULTS
PANTALOON
DHANUSH TECH
DAILY NIFTY GAINERS
SCRIPS RATE VOL.
(000)
PR.
CLOSE
NET
CHAN
GE
%
CHANG
E
Bharti Airtel
309.65 6409.00 296.20 13.45 4.54
DLF 281.45 13577.50 272.45 9.00 3.30
Wipro 415.95 2171.76 405.80 10.15 2.50
Power Grid
109.05 7905.51 106.85 2.20 2.06
Sun Pharma
811.55 1284.90 797.50 14.05 1.76
DAILY NIFTY LOOSERS
SCRIPS RATE VOL.
(000)
PR.
CLOSE
NET
CHAN
GE
%
CHAN
GE
Hindustan Unilever
455.40 2420.05 468.25 -12.85 -2.74
Coal India
331.70 2323.29 340.30 -8.60 -2.53
JP Associate
70.25 35866.74 71.80 -1.55 -2.16
Maruti Suzuki
1438.40 648.68 1467.50 -29.10 -1.98
HDFC 799.85 2776.08 815.05 -15.20 -1.86

.
MARKET CALLS
CASH
SCRIPS ACTION LEVEL 1ST
TARGET 2ND
TARGET STOP LOSS
ANDHRA BANK SELL 99.30 98.80 98.00 99.80
BHARTI AIRTEL BUY 309.90 311.90 314.90 307.90
FUTURE
SCRIPS ACTION LEVEL 1ST
TARGET 2ND
TARGET STOP LOSS
AUROBINDO PHARMA
SELL 180.35 179.35 177.85 181.35
AMBUJA BUY 198.90 199.90 200.90 197.90
Disclaimer
The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most.
Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable.
This material is for personal information and based upon it & takes no responsibility
The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE.
The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer.
All Rights Reserved. Investment in equity & bullion market has its own risks.
We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoever for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.